Yun Zhong
Stock Analyst at Wedbush
(4.02)
# 541
Out of 5,152 analysts
47
Total ratings
56.1%
Success rate
12.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Outperform | $240 → $273 | $241.38 | +13.10% | 4 | Feb 12, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $16.09 | +111.31% | 13 | Jan 23, 2026 | |
| RZLT Rezolute | Maintains: Neutral | $1 → $2 | $3.28 | -39.02% | 2 | Jan 8, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $33 | $13.71 | +140.70% | 3 | Dec 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $13.77 | +16.19% | 3 | Nov 6, 2025 | |
| IRD Opus Genetics | Initiates: Outperform | $8 | $4.57 | +75.05% | 1 | Oct 29, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $70 → $86 | $94.83 | -9.31% | 3 | Oct 28, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $18.14 | -0.77% | 2 | Sep 30, 2025 | |
| PASG Passage Bio | Maintains: Outperform | $3 → $40 | $8.44 | +373.93% | 3 | Aug 13, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $28 | $5.76 | +386.11% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $4.13 | +93.70% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.08 | +96.08% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $4.82 | +563.90% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $5.00 | +460.00% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.64 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $14.33 | +11.65% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $9.04 | +408.85% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.41 | +2,314.88% | 1 | May 5, 2021 |
Ascendis Pharma
Feb 12, 2026
Maintains: Outperform
Price Target: $240 → $273
Current: $241.38
Upside: +13.10%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $16.09
Upside: +111.31%
Rezolute
Jan 8, 2026
Maintains: Neutral
Price Target: $1 → $2
Current: $3.28
Upside: -39.02%
Wave Life Sciences
Dec 12, 2025
Maintains: Outperform
Price Target: $20 → $33
Current: $13.71
Upside: +140.70%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $13.77
Upside: +16.19%
Opus Genetics
Oct 29, 2025
Initiates: Outperform
Price Target: $8
Current: $4.57
Upside: +75.05%
Protagonist Therapeutics
Oct 28, 2025
Maintains: Outperform
Price Target: $70 → $86
Current: $94.83
Upside: -9.31%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $18.14
Upside: -0.77%
Passage Bio
Aug 13, 2025
Maintains: Outperform
Price Target: $3 → $40
Current: $8.44
Upside: +373.93%
Sagimet Biosciences
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $5.76
Upside: +386.11%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.13
Upside: +93.70%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.08
Upside: +96.08%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $4.82
Upside: +563.90%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $5.00
Upside: +460.00%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.64
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $14.33
Upside: +11.65%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $9.04
Upside: +408.85%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.41
Upside: +2,314.88%